Is triple therapy redefining first-line treatment in intermediate-advanced hepatocellular carcinoma?
Hepatology International · 2026-06 · 20 (3) · 556-558
DOI: 10.1007/s12072-026-11089-1 ↗Kurz gefasst
Editorial in der Zeitschrift Hepatology International, online erschienen am 19.04.2026. Verfasst von Shuntaro Obi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Teikyo University Chiba Medical Center, 3426-3 Anesaki, Ichihara, Chiba, 299-0111, Japan. obis@med.teikyo-u.ac.jp. Die Arbeit nennt 11 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Internal Medicine, Teikyo University Chiba Medical Center, 3426-3 Anesaki, Ichihara, Chiba, 299-0111, Japan. obis@med.teikyo-u.ac.jp.
- Department of Gastroenterology, Yamanashi Prefectural Central Hospital, Yamanashi, Japan.
- The University of Tokyo, Tokyo, Japan.
Zitieren
APA
Obi, S., & Omata, M. (2026). Is triple therapy redefining first-line treatment in intermediate-advanced hepatocellular carcinoma?. Hepatology International, 20(3), 556-558. https://doi.org/10.1007/s12072-026-11089-1
Vancouver
Obi S, Omata M. Is triple therapy redefining first-line treatment in intermediate-advanced hepatocellular carcinoma?. Hepatology International. 2026;20(3):556-558. doi:10.1007/s12072-026-11089-1
BibTeX
@article{Obi2026,
author = {Obi, Shuntaro and Omata, Masao},
title = {Is triple therapy redefining first-line treatment in intermediate-advanced hepatocellular carcinoma?},
journal = {Hepatology International},
year = {2026},
volume = {20},
number = {3},
pages = {556--558},
doi = {10.1007/s12072-026-11089-1}
}
EUVIMED